Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.
In two phase 3 clinical trials, OXYTROL patients experienced up to a 75% reduction in urinary incontinence episodes (Study 1 = 61% reduction, Study 2 = 75% reduction) compared to a 50% reduction in both placebo groups. Moreover, OXYTROL offers OAB patients continuous bladder control with a low incidence of drying side effects, such as dry mouth and constipation.
